Skip to main content
ATHE
NASDAQ Life Sciences

Alterity Therapeutics Proposes Massive Option Grant to Chairman and Executive, Signaling Extreme Potential Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.45
Mkt Cap
$61.182M
52W Low
$2.521
52W High
$7
52W Position info
37% above low
Off High info
51% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ATHE sits 37% above its 52-week low of $2.521 on light trading volume (0.3× avg).

Summary

Alterity Therapeutics proposes issuing 150 million options to its Chairman and another executive as compensation, which, if approved and exercised, could lead to over 800% dilution based on current market capitalization.


Key Events · Financing and Capital Events · ATHE

  • Proposed Option Grant

    The company proposes to issue 150,000,000 options to its Chairman, Julian Babarczy, and Lawrence Gozlan.

  • Compensation for Services

    These options are intended as payment for services rendered, with no cash consideration provided for the options themselves.

  • Low Exercise Price

    Each option has an exercise price of A$0.02 and an expiry date of June 26, 2031.

  • Significant Potential Dilution

    If all options are exercised, the number of outstanding shares would increase substantially, potentially leading to over 800% dilution based on the current market capitalization.


Analysis · ATHE · Life Sciences

Alterity Therapeutics has proposed a highly dilutive option grant of 150 million options to its Chairman, Julian Babarczy, and Lawrence Gozlan as compensation for services rendered. These options have a low exercise price of A$0.02 and, if approved by shareholders and subsequently exercised, would significantly increase the company's outstanding share count. Based on the current market capitalization and stock price, the potential issuance of 150 million shares could result in over 800% dilution, representing a substantial transfer of value and a major concern for existing shareholders. The proposal requires shareholder approval, highlighting the importance of the upcoming vote.

At the time of this filing, ATHE was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.2M. The 52-week trading range was $2.52 to $7.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATHE - Latest Insights

ATHE
Jun 30, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.92
Real-time Price: $4.59 info
Change: -$0.330 (-7%) info
Market Cap: $84.918M info
ATHE
Jun 17, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.81
Real-time Price: $4.59 info
Change: -$0.220 (-5%) info
Market Cap: $84.918M info
ATHE
Jun 16, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.44
Real-time Price: $4.59 info
Change: +$0.150 (+3%) info
Market Cap: $84.918M info
ATHE
Jun 15, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.21
Real-time Price: $4.59 info
Change: +$0.380 (+9%) info
Market Cap: $84.918M info
ATHE
Jun 12, 2026, 6:07 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $4.59 info
Change: +$0.590 (+15%) info
Market Cap: $84.918M info